Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Dual antiplatelet therapy consisting of aspirin and clopidogrel is the cornerstone of
treatment for prevention of atherothrombotic events in patients with coronary artery disease
(CAD) undergoing percutaneous coronary interventions (PCI). Many patients on dual
antiplatelet therapy in this setting may be affected by other thromboembolic conditions, in
particular atrial fibrillation, therefore having an indication to also receive oral
anticoagulation for stroke prevention. Thus, a considerable percentage of patients are under
"triple therapy" which consists of aspirin plus clopidogrel plus an oral anticoagulant. The
ever raising population with CAD warranting triple therapy and the growing number of patients
being treated with dabigatran underscores the importance of understanding the pharmacodynamic
effects of this treatment regimen.